BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17611561)

  • 21. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.
    Scielzo C; Ghia P; Conti A; Bachi A; Guida G; Geuna M; Alessio M; Caligaris-Cappio F
    J Clin Invest; 2005 Jun; 115(6):1644-50. PubMed ID: 15931393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
    López-Guerra M; Roué G; Pérez-Galán P; Alonso R; Villamor N; Montserrat E; Campo E; Colomer D
    Clin Cancer Res; 2009 Apr; 15(8):2767-76. PubMed ID: 19351760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.
    Ouillette P; Erba H; Kujawski L; Kaminski M; Shedden K; Malek SN
    Cancer Res; 2008 Feb; 68(4):1012-21. PubMed ID: 18281475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
    Pepper C; Majid A; Lin TT; Hewamana S; Pratt G; Walewska R; Gesk S; Siebert R; Wagner S; Kennedy B; Miall F; Davis ZA; Tracy I; Gardiner AC; Brennan P; Hills RK; Dyer MJ; Oscier D; Fegan C
    Br J Haematol; 2012 Feb; 156(4):499-507. PubMed ID: 22171799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin.
    Pepper C; Ward R; Lin TT; Brennan P; Starczynski J; Musson M; Rowntree C; Bentley P; Mills K; Pratt G; Fegan C
    Leukemia; 2007 Apr; 21(4):687-96. PubMed ID: 17287849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
    Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
    Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P; Corallini F; Barbarotto E; Melloni E; di Iasio MG; Tiribelli M; Zauli G
    J Cell Physiol; 2006 Apr; 207(1):158-64. PubMed ID: 16270354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of gene expression signatures for molecular classification in human leukemia cells.
    Song JH; Kim HJ; Lee CH; Kim SJ; Hwang SY; Kim TS
    Int J Oncol; 2006 Jul; 29(1):57-64. PubMed ID: 16773185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B-chronic lymphocytic leukemia cells contain both endogenous kappa immunoglobulin mRNA and critical immunoglobulin gene activation transcription factors.
    Zaknoen SL; Christian SL; Suen R; Van Ness B; Kay NE
    Leukemia; 1992 Jul; 6(7):675-9. PubMed ID: 1625486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
    Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
    Klobusická M; Kusenda J; Babusíková O
    Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendrimer-based nanoparticles for potential personalized therapy in chronic lymphocytic leukemia: Targeting the BCR-signaling pathway.
    Franiak-Pietryga I; Maciejewski H; Ostrowska K; Appelhans D; Voit B; Misiewicz M; Kowalczyk P; Bryszewska M; Borowiec M
    Int J Biol Macromol; 2016 Jul; 88():156-61. PubMed ID: 26987432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic lesions in chronic lymphocytic leukemia: clinical implications.
    Montserrat E; Moreno C
    Curr Opin Oncol; 2009 Nov; 21(6):609-14. PubMed ID: 19713841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
    Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
    Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia.
    Saint-Georges S; Quettier M; Bouyaba M; Le Coquil S; Laurienté V; Guittat L; Lévy V; Ajchenbaum-Cymbalista F; Varin-Blank N; Le Roy C; Ledoux D
    Oncotarget; 2016 Jul; 7(27):41031-41046. PubMed ID: 27127886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
    Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
    Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.
    Shukla A; Rai K; Shukla V; Chaturvedi NK; Bociek RG; Pirruccello SJ; Band H; Lu R; Joshi SS
    Blood; 2016 May; 127(19):2310-21. PubMed ID: 26809508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia.
    Dürig J; Dührsen U; Klein-Hitpass L; Worm J; Hansen JB; Ørum H; Wissenbach M
    Leukemia; 2011 Apr; 25(4):638-47. PubMed ID: 21358717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia.
    Rybka J; Butrym A; Wróbel T; Jaźwiec B; Bogucka-Fedorczuk A; Poręba R; Kuliczkowski K
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):147-150. PubMed ID: 28083607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement.
    Rodríguez A; Martínez N; Camacho FI; Ruíz-Ballesteros E; Algara P; García JF; Menárguez J; Alvaro T; Fresno MF; Solano F; Mollejo M; Martin C; Piris MA
    Clin Cancer Res; 2004 Oct; 10(20):6796-806. PubMed ID: 15501956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.